BUND FINANCE › Stocks › EW
Edwards Lifesciences Corporation (EW)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +15.46% above its 50-day average.
- It is +21.54% above its 200-day average (long-term uptrend).
- It sits at 92% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$5.2B | US$5.4B | US$5.0B | US$5.4B | US$6.1B |
| Net income | US$1.5B | US$1.5B | US$1.4B | US$4.2B | US$1.1B |
| EPS (diluted) | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
| Gross margin | 76.6% | 78.3% | 79.3% | 79.5% | 78.1% |
| Operating margin | 30.8% | 31.6% | 28.5% | 25.4% | 27.0% |
| Net margin | 28.7% | 28.3% | 28.0% | 76.8% | 17.7% |
| Free cash flow | US$1.4B | US$953.4M | US$629.5M | US$289.9M | US$1.3B |
| Total debt | US$690.3M | US$691.3M | US$685.1M | US$700.0M | US$705.4M |
| Cash | US$862.8M | US$769.0M | US$1.1B | US$3.0B | US$2.9B |
Compound annual growth: revenue 3.8% · net income -8.1% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 59.5x | 34.8x | 27.1x |
| EV / EBITDA | 35.3x | 30.9x | 16.5x |
| Operating margin | 25.5% | — | 3.6% |
| Net margin | 15.3% | — | -0.0% |
| Debt / equity | 0.29 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice